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ABSTRACT 
Objective: The objective of the present investigation was to design a multi particulate delivery system for site-specific delivery of 5-aminosalicylic 
acid (ASA) using natural polysaccharides (pectin) and pH-sensitive polymer (Eudragit S100) for the treatment of ulcerative colitis. This system is 
anticipated to protect the drug loss in the upper GI tract, which results from the inherent property of Eudragit S100 (ES), and deliver ASA in the 
colon only.  
Methods: The use of enteric polymers (ES) as the protective coating on the microspheres makes them able to release the drug at the particular pH 
of colonic fluid. A combined mechanism of release is used, which combines specific biodegradability of polymer and pH-dependent drug release 
from the coated microspheres. The effects of polymer concentration, stirring rate, and concentration of emulsifier on particle size and drug loading 
were studied. Pectin microspheres were prepared by emulsion dehydration method using different ratios of drug and polymer (1:2 to 1:4), stirring 
speeds (1000-3000 rpm) and emulsifier concentrations (1%-3% wt/vol). Eudragit -coating of pectin microspheres was prepared by oil-in-oil 
solvent evaporation method. Both the pectin microspheres and Eudragit-coated pectin microspheres were evaluated for surface morphology, 
particle size and size distribution, percentage drug entrapment, swell ability and In vitro drug release in pH progression media.  
Result: The release profile of 5-ASA from Eudragit-coated pectin microspheres was pH dependent. Hence, the drug released quickly at pH 7.5 but 
the release rate was much slower in acidic medium.  
Conclusion: The designed drug delivery system can be used as a tool for colon targeting of drugs. 
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INTRODUCTION 
Biodegradable pectin microspheres offer a novel approach for 
developing sustained release drug delivery systems that have 
potential for colonic drug delivery. In the controlled release area, 
biodegradable microspheres are one of the most useful devices to 
deliver materials in an effective, prolonged and safe manner. Pectin, 
a hetero saccharide derived from the cell wall of plants used as a 
gelling agent for scanning purpose. The degradation of pectin occurs 
mainly in the colon by pectinolytic enzymes secreted by 
microorganisms. As a result pectin has increasingly gained 
acceptance as the carrier polymer for sustained release and site 
specific delivery dosage forms, such as beads, pellets, tablets, and 
films. [1,2]. For colonic delivery of drugs, different approaches 
include the use of prodrugs, [3,4] pH-sensitive polymer coating, 
[5,6]and time-dependent formulations [7,8]. In addition, the use of 
biodegradable polymers such as azopolymer and polysaccharide (e. 
g., Pectin and Dextran) for colon targeting are also reported in the 
literature.[9,10]. Among the different approaches to achieve colon-
target drug delivery, the use of polymers, specifically biodegraded by 
colonic bacteria, proves better results. The pH-dependent systems 
exploit the generally accepted view that pH of the human GI tract 
increases progressively from the stomach (pH 2-3) to the small 
intestine (pH 6.5-7.0) to the colon (7.0-8.0),[11]. Most commonly 
used pH-dependent coating polymers are meth acrylic acid 
copolymer (i. e., Eudragit L100-55, Eudragit L100, and Eudragit 
S100), which dissolve at pH 5.5, 6.0, and 7.0, respectively. 
Pectin is a predominately linear polymer of mainly α-(1-4)-linked D-
galacturonic acid residues interrupted by 1, 2-linkedL-rhamnase 
residues. Pectin has a few hundred to about 1000building blocks per 
molecule. As pectin is soluble in water, it is not able to shield its drug 
load effectively during its passage through the stomach and small 
intestine. Hydrophilic polymer matrix systems are widely used in 
oral controlled drug delivery because of their flexibility to obtain a 
desirable drug release profile, cost-effectiveness, and broad 
regulatory acceptance,[12,13]. The ability of the hydrophilic polymer 
matrices to release an entrapped drug in aqueous medium and to 
regulate the release of such drug by control of swelling and cross-
linking makes them particularly suitable for controlled-release 
applications,[14]. These matrices can be applied for the release of 
both hydrophilic and hydrophobic drugs and charged solutes.  
5-ASA is a drug used for treating ulcerative colitis. The exact 
mechanism of 5-ASA is not known but is believed to reduce 
inflammation in the
The 5-ASA was a gift from S. A. Pharma (Saga r, India), pectin 
(Sigma-Aldrich) and Eudragit S-100 (Rohm, GmbH, Germany) were 
obtained from Alembic Ltd (Gujarat, India). Glutaraldehyde, castor 
oil and Magnesium Chloride were procured from Hi- media, India. 
Hydrochloric Acid procured from Qualigens Fine chemicals, India. 
Isopropyl alcohol, HPLC grade methanol and water was obtained 
 colon. Ulcerative colitis and other inflammatory 
diseases cause excessive production of chemicals, for example, 
prostaglandins, that produce inflammation in the colon. 
Prostaglandins are produced by the enzymes, cyclooxygenase and 
lipoxygenase. These enzymes are over-active in individuals with 
ulcerative colitis. 5-ASA may work by blocking the activity of 
cyclooxygenase and lipoxygenase, thereby, reducing the production 
of prostaglandins. Reduced production of prostaglandins decreases 
inflammation in the colon and the symptoms associated with 
ulcerative colitis. Site-specific delivery of 5-ASA may reduce the 
systemic side effects and provide effective and safe therapy that may 
reduce the dose and duration of therapy when compared with the 
conventional treatment. 
Microspheres of Eudragit S100 were developed for delivery of 5-
Aminosalicylic acid specifically into the colon. This type of advanced 
pharmaceutical dosage forms (Multi particulate systems) is of great 
practical importance for instance, for the treatment of ulcerative 
colitis. The present investigation reveals that Eudragit-coated pectin 
microspheres are promising controlled release carriers for colon-
targeted delivery of 5-ASA.  
MATERIALS AND METHODS  
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from Hi-Media Chemical (Bombay), India. All other materials used in 
dissolution studies were of analytical reagent grade and were used 
as received. 
Preparation of Eudragit-coated pectin microspheres 
Pectin microspheres were prepared by using a combined method i. 
e. water-in-oil (w/o) emulsification and cross linking method.15, 
whereas Eudragit coating of pectin microspheres was performed 
using oil-in-oil (o/o) solvent evaporation method, 16. For 
preparation of pectin microspheres, Pectin (3 g) was dissolved in 30 
ml of de ionized water and to it 5 ml of MgCl2 (5% w/v) solution was 
added. In a 1 liter beaker at 50±1°C, 5-ASA (1 g) was added to the 
pectin solution through syringe into a continuous oil phase (which 
consists of 300 ml of castor oil, 100 ml of isopropanol and 2% (w/v) 
span 80). The dispersion was stirred using a stainless steel stirrer at 
2000 rpm for 10 min and thereafter with continuous stirring,15 ml 
of glutaraldehyde was added to the beaker. The cross linking 
reaction was allowed to proceed for 3 hrs. Hardened microspheres 
were filtered, washed repeatedly with isopropanol and water, so as 
to remove castor oil and un reacted glutaraldehyde. The 
microspheres were dried under vacuum at 40°C overnight and kept 
in a desiccators.  
Similarly pectin microspheres were prepared by taking polymer: 
drug in a ratio of 1:2, 1:3 and 1:4, stirring rate 1000 rpm, 2000 rpm 
and 3000 rpm and emulsifier (span 80) concentration 1%, 2% and 
3%. Eudragit coating of pectin microspheres was performed using 
oil-in-oil (o/o) solvent evaporation method. 250 mg of Eudragit S-
100 was dissolved in 10 ml of organic solvent (2:1, ethanol: 
acetone). 50 mg of pectin microspheres were added to the above 
solution. This organic phase was then poured into 100 ml of light 
liquid paraffin containing 2% w/v span 80. To facilitate for the 
evaporation of solvent, the system was maintained under agitation 
speed of 1000 rpm at 40°C for 3 hrs. Finally the coated microspheres 
were washed with n-hexane and dried overnight in the vacuum 
desiccators. 
Surface morphology 
The shape and surface morphology of pectin microspheres and 
Eudragit coated pectin microspheres were investigated using 
scanning electron microscopy (SEM). The samples for SEM study 
were prepared by lightly sprinkling the formulation on a double-
adhesive tape stuck to an aluminum stub. The stubs were then 
coated with gold to a thickness of ~300 Å under an argon 
atmosphere using a gold sputter module in a high-vacuum 
evaporator. The coated samples were then randomly scanned and 
photomicrographs were taken with a scanning electron microscope. 
Particle size and particle size distribution  
The particle size and particle size distribution was measured in 
particle size analyzer (Malvern, USA). Microspheres were suspended 
in distilled water and the particle size and size distribution was 
determined using the software provided by the manufacturer.  
Swell ability 
A known weight (100 mg) of various ASA-loaded pectin 
microspheres and Eudragit-coated pectin microspheres were placed 
in enzyme-free simulated intestinal fluid (SIF, KH2PO4/ Na OH 
buffer, pH 7.4) and allowed to swell for the required period of time 
at 37°C ± 0.5°C in the dissolution apparatus (United States 
Pharmacopoeia [USP] XXIII, model DT-06, Eureka, Germany). The 
microspheres were periodically removed and blotted with filter 
paper; then their change in weight (after correcting for drug loss) 
was measured until attainment of equilibrium. The swelling ratio 
(SR) was then calculated using the following formula  
SR =
wg−  wo 
wo
 
Where SR indicates swelling ratio, wo is an initial weight of 
microspheres and wg 
Percentage drug entrapment 
is final weight of microspheres. 
The percentage of drug entrapped in the microspheres was 
determined by digesting the microspheres (50 mg) in sufficient 
saline phosphate buffer pH 7.4 for 48 hrs. It was centrifuged at 3000 
rpm for 30 min and the supernatant were analyzed. Spectro photo 
metrically at 267.7 nm. The percentage drug entrapment of coated 
pectin microspheres was determined in the same manner. 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑃𝑃𝑃𝑃𝑃𝑃 = {%𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑 } 
{%𝑃𝑃ℎ𝑃𝑃𝑑𝑑𝑃𝑃𝑃𝑃𝑃𝑃𝑑𝑑𝑃𝑃𝑒𝑒𝑑𝑑𝑑𝑑𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑 }
X 100 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑 = {𝑤𝑤𝑃𝑃𝑑𝑑𝑑𝑑 ℎ𝑃𝑃 𝑑𝑑𝑜𝑜  𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑  𝑑𝑑𝑃𝑃  𝑒𝑒𝑑𝑑𝑃𝑃𝑃𝑃𝑑𝑑𝑚𝑚𝑒𝑒 ℎ𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚 } 
{𝑤𝑤𝑃𝑃𝑑𝑑𝑑𝑑 ℎ𝑃𝑃 𝑑𝑑𝑜𝑜  𝑒𝑒𝑑𝑑𝑃𝑃𝑃𝑃𝑑𝑑𝑚𝑚𝑒𝑒 ℎ𝑃𝑃𝑃𝑃𝑃𝑃𝑚𝑚 }
X 100 
In vitro drug release studies in pH progression media 
Eudragit-coated pectin microspheres and uncoated pectin 
microspheres were evaluated for the in vitro drug release in pH 
progression media. An accurately weighed amount of microspheres, 
equivalent to 100 mg of 5-ASA, was added to 900 ml of dissolution 
medium and the release of 5-ASA from microspheres was 
investigated using rotating paddle dissolution test apparatus 
(Electro lab, India) at 100 rpm and 37±0.5°C. The simulation of 
gastrointestinal transit conditions was achieved by altering the pH of 
the dissolution medium. Initially it was kept at pH 1.2 for 2 hrs with 
0.1N H Cl. Then KH2PO4 (1.7 g) and Na2HPO4.2H2O (2.225 g) were 
added to the dissolution medium adjusting the pH 4.5 for 3rdand 
4thhr and adjusted with Na OH to 6.8 for 5thhr. After 5th
Pectin microspheres of ASA were successfully prepared by emulsion 
dehydration technique. The pectin microspheres were coated with 
Eudragit S100 by oil-in-oil solvent evaporation method, using coat: 
core ratio 5:1. Both the coated microspheres and uncoated 
microspheres were found to be of spherical shape (SEM). The 
method was optimized using different stirring rate and emulsifier 
concentration to produce microspheres of small size and narrow 
size distribution, high drug loading efficiency, and controlled drug 
release at pH progression media. 
hr, the pH of 
the dissolution medium was adjusted to 7.5 and maintained up to 
8hr. The final volume in all case was kept 900 ml. The samples were 
withdrawn from dissolution medium at various time intervals using 
a pipette fitted with micro-filter at its tips and analyzed Spectro 
photometrically at 267.7 nm.  
Statistical analysis 
The mean percentage of ASA released in pH progression media from 
both pectin microspheres and Eudragit-coated pectin microspheres 
was prepared by using various drug: polymer ratios and compared. 
The Student t test was used to find the statistical significance. A 
value of P < 0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Preparation of Eudragit-coated pectin microspheres 
 
Table 1: Formulations prepared by different approaches 
S. No. Formulation code Variables Values 
1 MA1 Drug: Polymer Ratio 1:2 
2 MA2  1:3 
3 MA3  1:4 
4 MB1 Emulsifier (Span80) concentration 1% w/v 
5 MB2  2% w/v 
6 MB3  3% w/v 
7 MC1 Stirring speed 1000 rpm 
8 MC2  2000 rpm 
9 MC3  3000 rpm 
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Table 2: Particle size of microspheres prepared by different formulation approaches 
S. No. Formulation code Mean diameter of microspheres (in μm) 
1 MA1 7.19 ±0.32 
2 MA2 15.06 ±0.24  
3 MA3 20.96 ±0.71  
4 MB1 22.40 ±0.53  
5 MB2 14.22 ±0.90  
6 MB3 6.59 ±0.35  
7 MC1 23.32 ±0.64  
8 MC2 17.81 ±0.85  
9 MC3 8.42 ±0.26  
 
Particle size and particle size distribution  
The particle size distributions of the microspheres of different 
formulation approaches are given in the table-2. 
As the drug: polymer ratio was increased from 1:2 to 1:4, the 
particle size of the microspheres increased from 7.19±0.32 μ m to 
20.96±0.71 μ m. The increase in size of the microspheres is due to an 
increase in viscosity of polymer solution with increasing 
concentration, which resulted in the formation of larger emulsion 
droplets and finally greater size of microspheres. As the 
concentration of the emulsifying agent (Span 80) was increased 
from 1% to 3% w/v, the particle size of the microspheres was 
decreased from 22.40±0.53 μ m to 6.59±0.35 μ m. This may be due 
to the decrease of interfacial energy between the two droplets and 
the presence of emulsifying agent in the cross linking medium, 
allowing the stabilization of the preformed microspheres to 
maintain their size until completion of the cross linking reaction. As 
the stirring rate was increased from 1000 rpm to 3000 rpm, the 
particle size of the microspheres was decreased from 23.32±0.64 μ 
m to 8.42±0.26 μ m. This may be due to formation of small size 
droplets on higher stirring rate. 
Swell ability  
The swell ability of different formulations performed in pH 1.2 and 
pH 7.5at 37±0.5°C are given in the Table3. The result indicates that 
swelling ratio was increased with an increase in drug: polymer ratio 
(from 1:2 to 1:4). It may be due to the denser crosslink between the 
pectin molecules, producing more packed structures in the 
formulations having more concentration of polymer (drug: polymer 
ratio less). 
  
Table 3: Swelling ratio of microspheres prepared by different formulation approaches 
S. No. Formulation code % Swelling ratio 
  In pH 1.2         In  pH 7.5  
1 MA1 2.63±0.11 1.83±0.05 
2 MA2 3.70±0.06 2.36±0.11 
3 MA3 4.59±0.08 3.27±0.02 
4 MB1 3.11±0.15 2.89±0.07 
5 MB2 3.29±0.12 3.26±0.06  
6 MB3 3.66±0.08 3.35±0.08 
7 MC1 2.96±0.06 2.23±0.06 
8 MC2 3.51±0.04 3.11±0.05 
9 MC3 4.12±0.06 3.90±0.10 
 
Table 4: Percentage drug entrapment of microspheres prepared by different formulation approaches 
S. No.  Formulation code %drug entrapment 
1 MA1 73.56±1.47 
2 MA2 79.92±1.19 
3 MA3 85.14±2.68 
4 MB1 72.15±0.79  
5 MB2 74.52±2.31  
6 MB3 75.16±1.20 
7 MC1 85.23±0.75  
8 MC2 81.01±0.21  
9 MC3 76.15±1.05  
The result indicates that on increasing drug: polymer ratio from 1:2 to 1:4, the entrapment efficiency was increased from 73.56±1.47 % to 
85.18±2.68 %. However, the change in the concentration of the emulsifying agent (span 80) had no significant effect in entrapment efficiency of the 
microspheres. But, As the stirring rate was increased from 1000 rpm to 3000 rpm, the entrapment efficiency was decreased from 85.23±0.75 % to 
76.15±1.05 %, which may be due to formation of small size microspheres with increased surface area. Higher stirring rate enhanced the diffusion of 
drug from such microspheres, resulting in the loss of drug from microspheres with a consequent lowering in the entrapment efficiency.  
 
In-vitro drug release  
In-vitro drug release was carried out for uncoated and Eudragit 
coated microspheres in pH progression medium. The in-vitro release 
from uncoated microspheres in pH progression media is 
represented in fig. 1. The result indicates that, when drug: polymer 
ratio was increased in the preparation of cross linked pectin 
microspheres, the in-vitro drug release from microspheres was 
decreased which may be due to increased path length for diffusion of 
drug molecule from microspheres. Drug release after 8 hrs was 
found to be 96.25±1.75% in case of microspheres prepared using 1:2 
drug: polymer ratio, while it was 88.65±1.26% for microspheres 
prepared with 1:4 drug: polymer ratio. 
Microspheres which were prepared using 1% w/v of emulsifying 
concentration, released 94.53±1.11% of drug after 8 hrs while those 
prepared using 2% and 3% w/v of emulsifying agent released 
95.23±2.01% and 96.23±1.71% of drug after the same period. The 
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result revealed that the concentration of emulsifying agent had no 
significant effect on drug release of the microspheres.  
Microspheres which were prepared at stirring speed of 3000 rpm, 
released 96.23±2.15% of drug after 8 hrs, while those prepared at 
2000 rpm released 92.43±1.18% of drug after 8 hrs. The size of the 
microspheres prepared at 1000 rpm was large and hence effective 
surface area was less in comparison to those prepared at 2000 rpm 
and 3000 rpm, which could probably be the reason for the lesser 
amount of drug release (89.15±2.56% after 8 hr) from microspheres 
prepared at 1000 rpm. 
Drug release from Uncoated and Eudragit coated microspheres 
in pH progression media  
The cumulative percentage drug release from Eudragit-coated pectin 
microspheres showed the desired rate, as there was no measurable 
drug release observed up to 2 hours in SGF (pH 1.2), while at pH 4.5, 
the drug release was quite insignificant (<2%) up to 4 hours. Drug 
release from Eudragit-coated pectin microspheres in pH progression 
media is represented in fig. 2. However in contrast, the in-vitro drug 
release study of the uncoated microspheres (fig 1) shows that more 
than 30% of drug release in GI Fluid, so less drug remains for colonic 
drug delivery. Hence Eudragit coated microspheres were considered 
to be more promising for colonic drug delivery. 
 








Eudragit coated pectin microspheres were found more suitable for 
colonic drug delivery in comparison to uncoated pectin microsphere. 
Different formulation approaches (i. e. drug: polymer ratio, 
emulsifier conc. and stirring speed) were carried out for preparing 
uncoated and coated microspheres. Among all the formulation 
approaches, in case of microspheres prepared using 1:2 drug: 
polymer ratio MA1 is considered to be the best, (as the %drug 
release is more i. e. 96.25%±1.75%).  
However, when stirring speed is considered, microspheres which 
were prepared at stirring speed of 3000 rpm, MC3 is found to be the 
best (96.23±2.15% drug release after 8 hrs). 
CONCLUSION  
The experimental results demonstrated that Eudragit-coated pectin 
microspheres have the potential to be used as a drug carrier for an 
effective colon-targeted delivery system. However it reduces the 
side effects of the drug caused by its absorption from the upper part 
of the GI tract when given in conventional dosage forms such as 
tablets and capsules. 
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